Applications of nucleic acid drugs for organ transplantation

Current Topics in Medicinal Chemistry

Volumn 12, Issue 15, 2012, Pages 1608-1612

  Suzuki, Jun ichi ^a   Isobe, Mitsuaki ^b   Morishita, Ryuichi ^c   Nagai, Ryozo ^d  

^a UNIVERSITY OF TOKYO   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

Adhesion molecules; Antisense oligodeoxynucleotides; Cytokines; Inflammation; Nucleic acid drug; Transplantation

Indexed keywords

ACTIVATOR PROTEIN 1 DECOY; ALEMTUZUMAB; ANTISENSE BCL X OLIGODEOXYNUCLEOTIDE; ANTISENSE CDK2 KINASE OLIGODEOXYNUCLEOTIDE; ANTISENSE MD 1 OLIGODEOXYNUCLEOTIDE; ANTISENSE OLIGODEOXYNUCLEOTIDE; ANTISENSE PCNA OLIGODEOXYNUCLEOTIDE; AZATHIOPRINE; CD40 ANTIGEN; CIS ELEMENT DOUBLE STRANDED DNA; CYCLIN DEPENDENT KINASE 2; CYCLOSPORIN; EDIFOLIGIDE; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 2; LIPOSOME; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NUCLEAR FACTOR KAPPA B DECOY; OLIGONUCLEOTIDE; PREDNISONE; PROTEIN BAX; PROTEIN BCL X; SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 DECOY; STAT1 PROTEIN; TACROLIMUS; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ACUTE GRAFT REJECTION; ANTIGEN PRESENTATION; APOPTOSIS; ARTERY INTIMA PROLIFERATION; CARDIAC GRAFT REJECTION; CELL CYCLE; CELL PROLIFERATION; CHRONIC GRAFT REJECTION; DRUG EFFECT; DRUG TARGETING; ENZYME ACTIVITY; EXPERIMENTAL MODEL; G1 PHASE CELL CYCLE CHECKPOINT; GENE CONTROL; GRAFT ARTERIAL DISEASE; GRAFT DYSFUNCTION; GRAFT REJECTION; HEART GRAFT; HEART TRANSPLANTATION; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE TRANSPLANTATION; KIDNEY ALLOGRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; NATURAL KILLER CELL; NEOINTIMA; NICK END LABELING; NONHUMAN; ORGAN TRANSPLANTATION; REGULATOR GENE; REVIEW; SINGLE DRUG DOSE; SKIN GRAFT REJECTION; SKIN TRANSPLANTATION; SMOOTH MUSCLE FIBER;

ANIMALS; DISEASE MODELS, ANIMAL; GENETIC THERAPY; GRAFT REJECTION; OLIGODEOXYRIBONUCLEOTIDES; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; ORGAN TRANSPLANTATION;

EID: 84867500786     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802612803531478     Document Type: Review

References (55)

1. Giannoukakis, N.; Thomson, A.; Robbins, P. Gene therapy in transplantation. Gene. Ther., 1999, 6, 1499-1511.
2. Guillot, C.; Le Mauff, B.; Cuturi, MC.; Anegon, I. Gene therapy in transplantation in the year 2000: moving towards clinical applications? Gene. Ther., 2000, 7, 14-19.
3. Chen, D.; Sung, R.; Bromberg, J.S. Gene therapy in transplantation. Transpl. Immunol., 2002, 9, 301-314.
4. Bagley, J.; Iacomini, J. Gene therapy progress and prospects: gene therapy in organ transplantation. Gene. Ther., 2003, 10, 605-611.
5. Moore, DJ.; Markmann, J.F.; Deng, S. Avenues for immunomodulation and graft protection by gene therapy in transplantation. Transpl. Int., 2006, 19, 435-445.
6. Morishita, R.; Gibbons, G.H.; Ellison, K.E.; Nakajima, M.; von der Leyen, H.; Zhang, L.; Kaneda, Y.; Ogihara, T.; Dzau, VJ. Intimal hyperplasia after vascular injury is inhibited by antisense cdk2 kinase oligonucleotides. J. Clin. Invest., 1994, 93, 1458-1464.
7. Morishita, R.; Aoki, M.; Ogihara, T. Does gene therapy become pharmacotherapy? Exp. Physiol., 2005, 90, 307-313.
8. Morishita, R. Perspective in progress of cardiovascular gene therapy. J. Pharmacol. Sci., 2004, 95, 1-8.
9. Nakagami, H.; Tomita, N.; Kaneda, Y.; Ogihara, T.; Morishita, R. Anti-oxidant gene therapy by NF κB decoy oligodeoxynucleotide. Curr. Pharm. Biotechnol., 2006, 7, 95-100.
10. Stehlik, J.; Edwards, LB.; Kucheryavaya, AY.; Aurora, P.; Christie, JD.; Kirk, R.; Dobbels, F.; Rahmel, AO.; Hertz, M.I. The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult heart transplant report--2010. J. Heart. Lung. Transplant., 2010, 29, 1089-1103.
11. Mitchell, RN. Graft vascular disease: immune response meets the vessel wall. Annu. Rev. Pathol., 2009, 4, 19-47.
12. Suzuki, J.; Isobe, M.; Morishita, R.; Nagai, R. Characteristics of chronic rejection in heart transplantation -Important elements of pathogenesis and future treatments-. Circ. J., 2010, 74, 233-239.
13. Tellides, G.; Pober, JS. Interferon-gamma axis in graft arteriosclerosis. Circ. Res., 2007, 100, 622-632.
14. Tsai, LH.; Harlow, E.; Meyerson, M. Isolation of the human cdk2 gene that encodes the cycline A and adenovirus E1A associated p33 kinase. Nature., 1991, 353, 174-177.
15. Koff, A.; Otsuki, M.; Polyak, K.; Roberts, JM.; Massague, J. Negative regulation of G1 in mammalian cells: inhibition of cycline Edependent kinase by TGF-beta. Science., 1993, 260, 536-539.
16. Suzuki, J.; Isobe, M.; Morishita, R.; Aoki, M.; Horie, S.; Okubo, Y.; Kaneda, Y.; Sawa, Y.; Matsuda, H.; Ogihara, T.; Sekiguchi, M. Prevention of graft coronary arteriosclerosis by antisense cdk2 kinase oligonucleotide. Nat. Med, 1997, 3, 900-903.
17. Schwartz, S.M.; Reidy, MA.; O'Brien, ER. Assessment of factors important in atherosclerotic occlusion and restenosis. Thromb. Haemost.; 1995, 74, 541-551.
18. Morishita, R.; Gibbons, G.H.; Ellison, K.E.; Nakajima, M.; Zhang, L.; Kaneda, Y.; Ogihara, T.; Dzau, VJ. Single intraluminal delivery of antisense cdc 2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc. Natl. Acad. Sci. USA., 1993, 90, 8474-8478.
19. Suzuki, J.; Isobe, M.; Morishita, R.; Nishikawa, T.; Amano, J.; Kaneda, Y. Prevention of cardiac allograft arteriosclerosis using antisense proliferating-cell nuclear antigen oligonucletide. Transplantation., 2000, 70, 398-400.
20. Geng, YJ.; Libby, P. Evidence for apoptosis in advanced human atheroma. Colocalization with interleukin-1 beta-converting enzyme. Am. J. Pathol., 1995, 147, 251-266.
21. Golstein, P. Controlling cell death. Science., 1997, 275, 1081-1082.
22. Gajewski, T.F.; Thompson, C.B. Apoptosis meets signal transduction: elimination of a BAD influence. Cell., 1996, 87, 589-592.
23. Pollman, M.J.; Hall, JL.; Mann, M.J.; Zhang, L.; Gibbons, G.H. Inhibition of neointimal cell bcl-x expression induces apoptosis and regression of vascular disease. Nat. Med., 1998, 4, 222-227.
24. Suzuki, J.; Isobe, M.; Morishita, R.; Nishikawa, T.; Amano, J.; Kaneda, Y. Antisense bcl-x oligonucleotide induces apoptosis and prevents arterial neointimal formation in murine cardiac allografts. Cardiovasc. Res., 2000, 45, 783-787.
25. Pagano, M.; Draetta, G.; Durr, J. Association of cdk 2 kinase with the transcription factor E2F during S phase. Science., 1992, 255, 1144-1147.
26. Weinster, S.J.; Prater, C.A.; Dean, D.C. Retinoblastoma protein switches the E2F site from positive to negative element. Nature., 1992, 358, 259-261.
27. Morishita, R.; Gibbons, GH.; Horiuchi, M.; Ellison, KE.; Nakajima, M.; Chang, L.; Kaneda, Y.; Ogihara, T.; Dzau, VJ. A gene strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc. Natl. Acad. Sci.USA., 1995, 92, 5855-5859.
28. Kawauchi, M.; Suzuki, J.; Morishita, R.; Wada, Y.; Izawa, A.; Tomita, N.; Amano, J.; Kaneda, Y.; Ogihara, T.; Takamoto, S.; Isobe, M. Gene therapy for attenuating cardiac allograft arteriopathy using ex vivo E2F decoy transfection by HVJ-AVE-liposome method in mice and nonhuman primates. Circ. Res., 2000, 87, 1063-1068.
29. May, M.J.; Ghosh, S. Signal transduction through NF-κB. Immunol. Today., 1998, 19, 80-88.
30. Sha, W.C. Regulation of immune responses by NF-κB/Rel transcription factor. J. Exp. Med., 1998, 187, 143-146.
31. Barnes, P.J.; Karin, M. Nuclear factor- B: a pivotal transcription factor in chronic inflammatory diseases. New. Engl. J. Med., 1997, 336, 1066-1071.
32. Suzuki, J.; Morishita, R.; Amano, J.; Kaneda, Y.; Isobe, M. Decoy against nuclear factor-κ B attenuates myocardial cell infiltration and arterial neointimal formation in murine cardiac allografts. Gene. Ther., 2000, 7, 1847-1852.
33. Roebuck, KA.; Finnegan, A. Regulation of intercellular adhesion molecule-1 (CD54) gene expression. J. Leukoc. Biol., 1999, 66, 876-888.
34. Jaruga, B.; Hong, F.; Kim, WH.; Gao, B. IFN-gamma/STAT1 acts as a proinflammatory signal in T cell-mediated hepatitis via induction of multiple chemokines and adhesion molecules: a critical role of IRF-1. Am. J. Physiol. Gastrointest. Liver. Physiol., 2004, 287, G1044-1052.
35. Hölschermann, H,; Stadlbauer, TH.; Wagner, AH.; Fingerhuth, H.; Muth, H.; Rong, S.; Güler, F.; Tillmanns, H.; Hecker, M. STAT-1 and AP-1 decoy oligonucleotide therapy delays acute rejection and prolongs cardiac allograft survival. Cardiovasc. Res., 2006, 71, 527-536.
36. Stadlbauer, TH.; Wagner, AH.; Hölschermann, H.; Fiedel, S.; Fingerhuth, H.; Tillmanns, H.; Bohle, RM.; Hecker, M. AP-1 and STAT-1 decoy oligodeoxynucleotides attenuate transplant vasculopathy in rat cardiac allografts. Cardiovasc. Res., 2008, 79, 698-705.
37. Nankivell, BJ.; Chapman, JR. Chronic allograft nephropathy: current concepts and future directions. Transplantation., 2006, 81, 643-654.
38. Stepkowski, SM.; Wang, ME.; Condon, TP.; Cheng-Flournoy, S.; Stecker, K.; Graham, M.; Qu, X.; Tian, L.; Chen, W.; Kahan, BD.; Bennett, CF. Protection against allograft rejection with intercellular adhesion molecule-1 antisense oligodeoxynucleotides. Transplantation., 1998, 66, 699-707.
39. Vos, I.H.; Govers, R.; Gröne, H.J.; Kleij, L.; Schurink, M.; De Weger, RA.; Goldschmeding, R.; Rabelink, TJ. NF B decoy oligodeoxynucleotides reduce monocyte infiltration in renal allografts. FASEB. J., 2000, 14, 815-822.
40. Azuma, H.; Tomita, N.; Kaneda, Y.; Koike, H.; Ogihara, T.; Katsuoka, Y.; Morishita, R. Transfection of NFkB-decoy oligodeoxynucleotides using efficient ultrasound-mediated gene transfer into donor kidneys prolonged survival of rat renal allografts. Gene.Ther., 2003, 10, 415-425.
41. Ohmori, K.; Takeda, S.; Miyoshi, S.; Minami, M.; Nakane, S.; Ohta, M.; Sawa, Y.; Matsuda, H. Attenuation of lung injury in allograft rejection using NF-κB decoy transfection-novel strategy for use in lung transplantation. Eur. J. Cardio-thoracic. Sur., 2005, 27, 23-27.
42. Xu, M.; Suo, Y.; Gong, J.; Zhang, M.; Yan, L. Augmented regeneration of partial liver allograft induced by nuclear factor- B decoy oligodeoxynucleotides-modified dendritic cells. World. J. Gastroenterol., 2004, 10, 573-578.
43. Xu, M.; Suo, Y.; Gong, J.; Zhang, M.; Yan, L. Prolongation of liver allograft survival by dendritic cells modified with NFB decoy oligodeoxynucleotides. World. J. Gastroenterol., 2004, 10, 2361-2368.
44. Stojanovic, T.; Scheele, L.; Wagner, A.H.; Middel, P.; Bedke, J.; Lautenschlager, I.; Leister, I.; Panzner, S.; Hecker, M. STAT-1 decoy oligonucleotide improves microcirculation and reduces acute rejection in allogeneic rat small bowel transplants. Gene. Ther., 2007, 14, 883-890.
45. Hadidi, S.; Chen, Z.; Phillips, J.; Yu, K.; Gorczynski, R.M. Antisense deoxyoligonucleotides or antibodies to murine MD1 inhibit rejection of allogeneic and xenogeneic skin grafts in C3H mice. Transplantation., 2002, 73, 1771-1779.
46. Zhang, X.; Zhang, B.C.; Chen, F.L.; Xiang, S.; Chang, H.M.; Zhou, D.F.; Du, J, Yuan.; and Z K, Chen. Inhibition of MD-1 Expression by Immunosuppressants or Antisense Oligodeoxynucleotides on Skin Allograft Survival in Mice. Transplantat. Proc., 2005, 37, 1965-1967.
47. Mann, M.J.; Whittemore, A.D.; Donaldson, M.C.; Belkin, M.; Conte, M.S.; Polak, J.F.; Orav, E.J.; Ehsan, A.; Dell'Acqua, G.; Dzau, VJ. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, con trial. Lancet., 1999, 354, 1493-1498.
48. Alexander, J.H.; Hafley, G.; Harrington, R.A.; Peterson, E.D.; Ferguson, T.B, Jr.; Lorenz, T.J.; Goyal, A.; Gibson, M.; Mack, M.J.; Gennevois, D.; Califf, R.M.; Kouchoukos, NT.; PREVENT IV Investigators. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA., 2005, 294, 2446-2454.
49. Suzuki, J.; Ito, H.; Gotoh, R.; Morishita, R.; Egashira, K.; Isobe, M. Initial clinical cases using an NF-κB decoy at the site of the coronary stenting for prevention of restenosis. Circ. J., 2004, 68, 270-271.
50. Egashira, K.; Suzuki, J.; Ito, H.; Aoki, M.; Isobe, M.; Morishita, R.; for, INDOR, Study, Group. Long-term follow up of initial clinical cases with NF-kB decoy oligodeoxynucleotide transfection at the site of the coronary stenting. J. Gene. Med., 2008, 10, 805-809.
51. Suzuki, J.; Tezuka, D.; Morishita, R.; Isobe, M. An initial case of suppressed restenosis with nuclear factor- B decoy transfection after percutaneous coronary intervention. J. Gene. Med., 2009, 11, 89-91.
52. Morris, MJ.; Tong, WP.; Cordon-Cardo, C.; Drobnjak, M.; Kelly, WK.; Slovin, SF.; Terry, KL.; Siedlecki, K,; Swanson, P.; Rafi, M.; DiPaola, RS.; Rosen, N.; Scher, HI. Phase I trial of Bcl-2 anti sense oligonucleotide (G3139) administered by continuous intraveneous infusion in patients with advanced cancer. Clin. Cancer. Res., 2002, 8, 679-683.
53. Cursiefen, C.; Bock, F.; Horn, F.K.; Kruse, F.E.; Seitz, B.; Borderie, V.; Früh, B.; Thiel, M.A.; Wilhelm, F.; Geudelin, B.; Descohand, I.; Steuhl, K.P.; Hahn, A.; Meller, D. GS-101 antisense oligonucleotide eye drops inhibit corneal neovascularization: interim results of a randomized phase II trial. Ophthalmology., 2009, 116, 1630-1637.
54. Miyake, T.; Aoki, M.; Osako, M.K.; Shimamura, M.; Nakagami, H; Morishita, R. Systemic administration of ribbon-type decoy oligodeoxynucleotide against nuclear factor B and ets prevents abdominal aortic aneurysm in rat model. Mol. Ther., 2011, 19, 181-187.
55. Suzuki, J.; Isobe, M.; Morishita, R.; Nagai, R. Nucleic acid drugs for prevention of cardiac rejection. J. Biomed. Biotech., 2009, 2009, Article ID 916514, 5 pages.